When vital medical devices run short: government plans reporting duty
Companies are to report delivery interruptions for certain vital medical devices digitally in future. The consultation runs until the end of January; the obligation is not yet in force.
A supply interruption for a medical product can quickly become serious for hospitals, medical practices and patients. The federal government therefore wants to recognise earlier where such bottlenecks are emerging. On 14 October 2026, the Federal Department of Economic Affairs, Education and Research opened the consultation on the planned reporting office for vital medical devices.
The core of the proposal is simple: companies should in future report supply bottlenecks and delivery interruptions for certain medical products. The reports are intended to give the Federal Office for National Economic Supply, known as BWL, a better overview. According to the federal government, they would be the basis for preparing economic intervention measures if required.
The distinction matters. This is not a blanket reporting obligation covering every plaster, every measuring device or every delivery in the healthcare sector. The federal government classifies as vital those items that are indispensable in healthcare and whose absence can directly threaten patients' lives or lead to serious health damage. Which specific products should fall under the new obligation is to be determined by the National Economic Supply office.
The model is the medicines reporting office
For vital human medicines, such an instrument already exists. Suppliers of reportable active substances must notify the reporting office of supply bottlenecks, delivery interruptions or market withdrawals. BWL uses the information together with further market enquiries to assess the supply situation and, where necessary, initiate measures. Since mid-June 2026, the digital medicines platform has also been developed into a proactive early warning system.
For the planned medical devices reporting office, the federal government intends to use this proven platform as well. That is meant to create synergies and keep the effort as small as possible. The entire process is to run electronically. The approach follows the so-called once-only principle: standard data should be collected and reused only once wherever possible, instead of companies having to supply the same details repeatedly to different bodies.
The starting point explains why the government is pushing the project forward. BWL notes that supply disruptions for medicines and medical devices have increased in recent years. Global, complex production and supply chains can be vulnerable; during the Covid-19 pandemic this became particularly visible with protective material, ventilators and other goods. Monitoring does not prevent a shortage on its own, but it can create time to examine alternatives, stock levels or other measures.
What the reporting requirement can achieve – and what it cannot
A reporting obligation is above all an instrument for situational awareness and early warning. It is not a guarantee that a product will be available at all times. Nor does the federal government promise with this proposal to bridge every bottleneck through state stockpiles. For medicines, there are reporting and in some cases stockholding obligations for certain active substances; for medical devices, the discussion now concerns first of all the legal basis for recording the situation.
That also matters for public expectations. A report to the new office would not be equivalent to immediate replacement procurement. Rather, it should show whether an outage is likely to be so important and so broadly felt that further steps become necessary. Which measures would be legally possible, proportionate and effective in an individual case depends on the product and on the supply situation.
What is certain
The timetable for the consultation is certain: comments can be submitted until 28 January 2027. The federal government aims to bring the new reporting obligation into force on 1 August 2027. It is also certain that the planned office will be located at BWL and closely modelled on the existing medicines reporting office.
What is still open
What is not yet binding, by contrast, is which medical devices will be included in the catalogue, who must report in detail, which thresholds apply and which data should be transmitted exactly. These questions belong to the ordinance and to the outcome of the consultation. It likewise remains to be seen whether the planned start date can be kept after the consultation and the enactment of the legal basis.
For patients, this does not imply any action to take. Anyone who needs a specific aid or a treatment should, if unsure, continue to approach the treating specialist or the pharmacy – and not wait for a future monitoring system. Politically, the announcement is a step towards greater transparency about critical supply chains. Operationally, it is still a proposal on which comments can now be submitted.
